Table 1.
Demographic and baseline characteristics of US patients enrolled in GIDEON by TACE subgroup
| n (%) | No TACE n=318 | Group A Prior TACE n=158 | Group B Concomitant TACE n=29 | Group C Prior and Concomitant TACE n=38 |
|---|---|---|---|---|
| Sex | ||||
| Male | 247 (78) | 131 (83) | 22 (76) | 28 (74) |
| Age, years | ||||
| <65 | 201 (63) | 98 (62) | 20 (69) | 30 (79) |
| 65–<75 | 81 (26) | 36 (23) | 8 (28) | 5 (13) |
| ≥75 | 36 (11) | 24 (15) | 1 (3) | 3 (8) |
| ECOG PSa | ||||
| 0/1 | 206 (65) | 102 (65) | 20 (69) | 32 (85) |
| ≥2 | 63 (21) | 35 (22) | 5 (17) | 5 (13) |
| Etiologyb | ||||
| Hepatitis B virus infection | 51 (16) | 18 (11) | 2 (7) | 4 (11) |
| Hepatitis C virus infection | 166 (52) | 88 (56) | 21 (72) | 24 (63) |
| Alcohol use | 124 (39) | 59 (37) | 15 (52) | 16 (42) |
| Other | 41 (13) | 25 (16) | 2 (7) | 5 (13) |
| Unknown | 36 (11) | 14 (9) | 1 (3) | 3 (8) |
Data refer to the safety population (n=563).
a
ECOG missing for 78 (14%) patients.
b
Patients may have >1.